Emerald Advisers LLC Has $9.32 Million Position in Quanterix Co. (NASDAQ:QTRX)

Emerald Advisers LLC lifted its holdings in shares of Quanterix Co. (NASDAQ:QTRX) by 5.6% during the third quarter, HoldingsChannel reports. The firm owned 719,217 shares of the company’s stock after acquiring an additional 38,230 shares during the quarter. Emerald Advisers LLC’s holdings in Quanterix were worth $9,321,000 as of its most recent SEC filing.

A number of other hedge funds also recently modified their holdings of the business. Allspring Global Investments Holdings LLC raised its position in Quanterix by 22.3% in the 1st quarter. Allspring Global Investments Holdings LLC now owns 12,844 shares of the company’s stock valued at $303,000 after buying an additional 2,340 shares during the last quarter. Principal Financial Group Inc. raised its position in Quanterix by 145.8% in the 1st quarter. Principal Financial Group Inc. now owns 26,824 shares of the company’s stock valued at $632,000 after buying an additional 15,909 shares during the last quarter. Easterly Investment Partners LLC raised its position in Quanterix by 551.1% in the 1st quarter. Easterly Investment Partners LLC now owns 78,734 shares of the company’s stock valued at $1,855,000 after buying an additional 66,642 shares during the last quarter. Williams Jones Wealth Management LLC. acquired a new stake in Quanterix in the 1st quarter valued at approximately $1,327,000. Finally, State Board of Administration of Florida Retirement System raised its position in Quanterix by 42.1% in the 1st quarter. State Board of Administration of Florida Retirement System now owns 14,341 shares of the company’s stock valued at $338,000 after buying an additional 4,250 shares during the last quarter. Institutional investors and hedge funds own 86.48% of the company’s stock.

Insider Transactions at Quanterix

In other Quanterix news, Director David R. Walt bought 47,000 shares of Quanterix stock in a transaction dated Tuesday, August 20th. The stock was bought at an average cost of $13.29 per share, for a total transaction of $624,630.00. Following the purchase, the director now owns 1,487,342 shares of the company’s stock, valued at $19,766,775.18. The trade was a 0.00 % increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 6.90% of the stock is currently owned by corporate insiders.

Quanterix Stock Up 1.6 %

Shares of NASDAQ QTRX traded up $0.21 during midday trading on Friday, hitting $13.43. 383,841 shares of the company’s stock were exchanged, compared to its average volume of 336,757. Quanterix Co. has a 12 month low of $10.50 and a 12 month high of $29.70. The company’s 50 day moving average price is $12.71 and its 200 day moving average price is $14.09. The firm has a market capitalization of $515.44 million, a PE ratio of -12.79 and a beta of 1.36.

Quanterix (NASDAQ:QTRX) last issued its earnings results on Thursday, August 8th. The company reported ($0.25) EPS for the quarter, missing the consensus estimate of ($0.23) by ($0.02). Quanterix had a negative return on equity of 11.52% and a negative net margin of 30.71%. The business had revenue of $34.38 million for the quarter, compared to the consensus estimate of $34.19 million. During the same quarter in the prior year, the firm posted ($0.16) earnings per share. On average, equities research analysts anticipate that Quanterix Co. will post -0.88 EPS for the current year.

Wall Street Analyst Weigh In

A number of equities research analysts recently issued reports on the company. Scotiabank dropped their target price on Quanterix from $32.00 to $28.00 and set a “sector outperform” rating on the stock in a research report on Monday, August 12th. TD Cowen decreased their price target on Quanterix from $17.00 to $15.00 and set a “hold” rating for the company in a research note on Friday, August 9th. Finally, The Goldman Sachs Group decreased their price target on Quanterix from $35.00 to $24.00 and set a “buy” rating for the company in a research note on Tuesday, July 9th.

Quanterix Company Profile

Quanterix Corporation, a life sciences company, engages in development and marketing of digital immunoassay platforms that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company offers HD-X instrument, a protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection in an expanded range of applications.